NCT02019667View on ClinicalTrials.gov

Phase 2 Clinical Trial of SGS-742 Therapy in Succinic Semialdehyde Dehydrogenase Deficiency

PHASE2CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

January 31, 2019

Study Completion Date

April 3, 2019

Conditions
Metabolic DiseaseSeizures
Interventions
DRUG

SGS-742

DRUG

Placebo

Trial Locations (2)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

Unknown

Washington State University, Pullman

All Listed Sponsors
lead

National Institute of Neurological Disorders and Stroke (NINDS)

NIH

NCT02019667 - Phase 2 Clinical Trial of SGS-742 Therapy in Succinic Semialdehyde Dehydrogenase Deficiency | Biotech Hunter | Biotech Hunter